Bristol-Myers Squibb and Exelixis Sign Cancer Deal
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 103 (Table of Contents)
Published: 12 Dec-2008
DOI: 10.3833/pdr.v2008.i103.101 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb (BMS) and Exelixis are to collaborate on the development of two of Exelixis’ novel clinical-stage anticancer compounds, XL184 and XL281...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS